Simon J Patton
Overview
Explore the profile of Simon J Patton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fairley J, Badrick T, Denis M, Dimitrova L, Goodall R, Maas J, et al.
Virchows Arch
. 2023 May;
485(4):717-722.
PMID: 37202567
Demand for large-scale tumour profiling across cancer types has increased in recent years, driven by the emergence of targeted drug therapies. Analysing alternations in plasma circulating tumour DNA (ctDNA) for...
2.
Esposito Abate R, Cheetham M, Fairley J, Pasquale R, Sacco A, Nicola W, et al.
Virchows Arch
. 2022 Dec;
482(2):357.
PMID: 36482100
No abstract available.
3.
Esposito Abate R, Cheetham M, Fairley J, Pasquale R, Sacco A, Nicola W, et al.
Virchows Arch
. 2022 Nov;
482(2):347-355.
PMID: 36355212
Tumor mutational burden (TMB) has recently been approved as an agnostic biomarker for immune checkpoint inhibitors. However, methods for TMB testing have not yet been standardized. The International Quality Network...
4.
Penault-Llorca F, Kerr K, Garrido P, Thunnissen E, Dequeker E, Normanno N, et al.
Virchows Arch
. 2022 Jul;
481(3):351-366.
PMID: 35857103
The diagnostic work-up for non-small cell lung cancer (NSCLC) requires biomarker testing to guide therapy choices. This article is the second of a two-part series. In Part 1, we summarised...
5.
Penault-Llorca F, Kerr K, Garrido P, Thunnissen E, Dequeker E, Normanno N, et al.
Virchows Arch
. 2022 Jul;
481(3):335-350.
PMID: 35857102
Biomarker testing is crucial for treatment selection in advanced non-small cell lung cancer (NSCLC). However, the quantity of available tissue often presents a key constraint for patients with advanced disease,...
6.
Fairley J, Cheetham M, Patton S, Rouleau E, Denis M, Dequeker E, et al.
BMC Cancer
. 2022 Jul;
22(1):759.
PMID: 35820813
Background: Circulating cell free DNA (cfDNA) testing of plasma for EGFR somatic variants in lung cancer patients is being widely implemented and with any new service, external quality assessment (EQA)...
7.
Froelich M, Capoluongo E, Kovacs Z, Patton S, Lianidou E, Haselmann V
Clin Chem Lab Med
. 2022 Feb;
60(6):821-829.
PMID: 35218176
Disruptive imaging and laboratory technologies can improve clinical decision processes and outcomes in oncology. However, certain obstacles must be overcome before these technologies can be fully implemented as part of...
8.
Fenizia F, Wolstenholme N, Fairley J, Rouleau E, Cheetham M, Horan M, et al.
Virchows Arch
. 2021 Apr;
479(6):1067-1072.
PMID: 33856555
While tumour mutation burden (TMB) is emerging as a possible biomarker for immune-checkpoint inhibitors (ICI), methods for testing have not been standardised as yet. In April 2019, the International Quality...
9.
van Casteren K, Keppens C, Schuuring E, Deans Z, Normanno N, Patton S, et al.
J Mol Diagn
. 2020 Mar;
22(6):736-747.
PMID: 32205291
Liquid biopsies have emerged as a useful addition to tissue biopsies in molecular pathology. Literature has shown lower laboratory performances when a new method of variant analysis is introduced. This...
10.
Radke T, Patton S, Pantazoglou E, Sass J, Thun S
Eur J Hum Genet
. 2020 Feb;
28(5):558-566.
PMID: 32055015
Modern diagnostic methods (next-generation sequencing) are one of the current hopes with regard to a personalised medicine. By applying detailed genetic analysis, it is possible to not only improve the...